Ruolo della farmacogenetica nella identificazione della migliore strategia terapeutica per il paziente affetto da carcinoma polmonare non a piccole cellule

Translated title of the contribution: Role of pharmacogenetics in choosing the best therapeutic strategy for non-small cell lung cancer patients

Katia Danza, Daniela Petriella, Domenico Galetta, Ettore Fistola, Rosamaria Pinto, Brunella Pilato, Marianna Martinucci, Massimo Bonucci, Stefania Tommasi, Gianmauro Numico, Nicola Silvestris

Research output: Contribution to journalArticle

Abstract

Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in many countries. The carcinogenesis of this malignancy is characterized by different genetic and epigenetic alterations. Knowledge of the signal transduction pathways specific to neoplastic cells has recently led to the development of a targeted approach, called "target therapy". The aim of this therapeutic strategy is to single out small molecules or monoclonal antibodies directed against molecular targets. Recent findings have revealed EGFR mutations in lung cancer cells and have shown their predictive role in the response to EGFR Tyrosine Kinase Inhibitors (EGFR-TKI). These pharmacogenetic approach studies have allowed patients who might benefit from a specific antineoplastic treatment to be selected without the risk of useless severe toxicity.

Original languageItalian
Pages (from-to)187-193
Number of pages7
JournalTrends in Medicine
Volume9
Issue number4
Publication statusPublished - Oct 2009

Fingerprint

Pharmacogenetics
Non-Small Cell Lung Carcinoma
Epigenomics
Antineoplastic Agents
Protein-Tyrosine Kinases
Cause of Death
Signal Transduction
Lung Neoplasms
Neoplasms
Carcinogenesis
Therapeutics
Monoclonal Antibodies
Mutation

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology (medical)

Cite this

Ruolo della farmacogenetica nella identificazione della migliore strategia terapeutica per il paziente affetto da carcinoma polmonare non a piccole cellule. / Danza, Katia; Petriella, Daniela; Galetta, Domenico; Fistola, Ettore; Pinto, Rosamaria; Pilato, Brunella; Martinucci, Marianna; Bonucci, Massimo; Tommasi, Stefania; Numico, Gianmauro; Silvestris, Nicola.

In: Trends in Medicine, Vol. 9, No. 4, 10.2009, p. 187-193.

Research output: Contribution to journalArticle

@article{e7c78ec464a14d389a1a43394eb6d48a,
title = "Ruolo della farmacogenetica nella identificazione della migliore strategia terapeutica per il paziente affetto da carcinoma polmonare non a piccole cellule",
abstract = "Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in many countries. The carcinogenesis of this malignancy is characterized by different genetic and epigenetic alterations. Knowledge of the signal transduction pathways specific to neoplastic cells has recently led to the development of a targeted approach, called {"}target therapy{"}. The aim of this therapeutic strategy is to single out small molecules or monoclonal antibodies directed against molecular targets. Recent findings have revealed EGFR mutations in lung cancer cells and have shown their predictive role in the response to EGFR Tyrosine Kinase Inhibitors (EGFR-TKI). These pharmacogenetic approach studies have allowed patients who might benefit from a specific antineoplastic treatment to be selected without the risk of useless severe toxicity.",
keywords = "Anti-EGFR, NSCLC, Pharmacogenetics, Tyrosine-kinase inhibitors",
author = "Katia Danza and Daniela Petriella and Domenico Galetta and Ettore Fistola and Rosamaria Pinto and Brunella Pilato and Marianna Martinucci and Massimo Bonucci and Stefania Tommasi and Gianmauro Numico and Nicola Silvestris",
year = "2009",
month = "10",
language = "Italian",
volume = "9",
pages = "187--193",
journal = "Trends in Medicine",
issn = "1594-2848",
publisher = "Pharma Project Group Edizioni Scientifiche (PPG)",
number = "4",

}

TY - JOUR

T1 - Ruolo della farmacogenetica nella identificazione della migliore strategia terapeutica per il paziente affetto da carcinoma polmonare non a piccole cellule

AU - Danza, Katia

AU - Petriella, Daniela

AU - Galetta, Domenico

AU - Fistola, Ettore

AU - Pinto, Rosamaria

AU - Pilato, Brunella

AU - Martinucci, Marianna

AU - Bonucci, Massimo

AU - Tommasi, Stefania

AU - Numico, Gianmauro

AU - Silvestris, Nicola

PY - 2009/10

Y1 - 2009/10

N2 - Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in many countries. The carcinogenesis of this malignancy is characterized by different genetic and epigenetic alterations. Knowledge of the signal transduction pathways specific to neoplastic cells has recently led to the development of a targeted approach, called "target therapy". The aim of this therapeutic strategy is to single out small molecules or monoclonal antibodies directed against molecular targets. Recent findings have revealed EGFR mutations in lung cancer cells and have shown their predictive role in the response to EGFR Tyrosine Kinase Inhibitors (EGFR-TKI). These pharmacogenetic approach studies have allowed patients who might benefit from a specific antineoplastic treatment to be selected without the risk of useless severe toxicity.

AB - Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in many countries. The carcinogenesis of this malignancy is characterized by different genetic and epigenetic alterations. Knowledge of the signal transduction pathways specific to neoplastic cells has recently led to the development of a targeted approach, called "target therapy". The aim of this therapeutic strategy is to single out small molecules or monoclonal antibodies directed against molecular targets. Recent findings have revealed EGFR mutations in lung cancer cells and have shown their predictive role in the response to EGFR Tyrosine Kinase Inhibitors (EGFR-TKI). These pharmacogenetic approach studies have allowed patients who might benefit from a specific antineoplastic treatment to be selected without the risk of useless severe toxicity.

KW - Anti-EGFR

KW - NSCLC

KW - Pharmacogenetics

KW - Tyrosine-kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=75749132849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749132849&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:75749132849

VL - 9

SP - 187

EP - 193

JO - Trends in Medicine

JF - Trends in Medicine

SN - 1594-2848

IS - 4

ER -